1418-DHA Potentiates Regorafenib and Anti-PD-1

This research paper explores how KRAS mutations cause resistance to a combination treatment of regorafenib and anti-PD-1 therapy in patients with colorectal cancer liver metastases. The authors identified dihydroartemisinin (DHA), a common anti-malarial drug, as a powerful agent capable of selectively degrading mutant KRAS proteins through the autophagy-lysosome pathway. Through various preclinical models, the study demonstrates that DHA enhances the effectiveness of immunotherapy by restoring interferon responses and promoting a more aggressive immune cell environment within tumors. Furthermore, the findings suggest that DHA helps overcome resistance by inhibiting ERBB signaling pathways typically activated during standard targeted therapy. Ultimately, the source proposes a promising new combinatorial therapeutic strategy for treating high-mortality, KRAS-driven malignancies.References:Huang N, Wang L, Deng H, et al. Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases[J]. Cell Death & Disease, 2026.前往小宇宙评论区与主播互动